EDITORIAL
Published on 15 Jul 2024
Editorial: Targeting mitochondrial dysfunction for the diagnosis and treatment of Alzheimer’s and cognitive-related diseases
doi 10.3389/fphar.2024.1455646
- 515 views
- Frontiers in Pharmacology
- Neuropharmacology
- Research Topics
- Targeting mitochondrial dysfunction for the diagnosis and treatment of Alzheimer's and cognitive-related diseases
Targeting mitochondrial dysfunction for the diagnosis and treatment of Alzheimer's and cognitive-related diseases
4,072
Total downloads
12k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 17 Apr 2024
Investigation of the shared biological mechanisms and common biomarker APTAF1 of sleep deprivation and mild cognitive impairment using integrated bioinformatics analysis
doi 10.3389/fphar.2024.1387569
- 1,313 views
- 1 citation
ORIGINAL RESEARCH
Published on 19 Sep 2023
Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
doi 10.3389/fphar.2023.1276179
- 1,661 views
- 2 citations
ORIGINAL RESEARCH
Published on 26 Jun 2023
Mapping trends and hotspots of mitochondrial dysfunction in Alzheimer’s disease from 2013 to 2022: a bibliometric analysis of global research
doi 10.3389/fnins.2023.1199625
- 2,339 views
- 3 citations
ORIGINAL RESEARCH
Published on 09 Jan 2023
Malvidin alleviates mitochondrial dysfunction and ROS accumulation through activating AMPK-α/UCP2 axis, thereby resisting inflammation and apoptosis in SAE mice
doi 10.3389/fphar.2022.1038802
- 3,784 views
- 25 citations
Published in
Frontiers in Pharmacology
Neuropharmacology
Participating Journals
Frontiers in Neuroscience
- 3.2 impact factor
- 6.2 citescore